Literature DB >> 33424833

Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.

Deborah L Cross1, Marije K Verheul1, Michael D Leipold2, Gerlinde Obermoser2, Celina Jin1, Elizabeth Jones1, Joshua S Starr1, Irina Mohorianu1, Christoph J Blohmke1, Holden T Maecker2, Giorgio Napolitani3, Jennifer Hill1, Andrew J Pollard1.   

Abstract

Vi-polysaccharide conjugate vaccines are efficacious against cases of typhoid fever; however, an absolute correlate of protection is not established. In this study, we investigated the leukocyte response to a Vi-tetanus toxoid conjugate vaccine (Vi-TT) in comparison with a plain polysaccharide vaccine (Vi-PS) in healthy adults subsequently challenged with Salmonella Typhi. Immunological responses and their association with challenge outcome was assessed by mass cytometry and Vi-ELISpot assay. Immunization induced significant expansion of plasma cells in both vaccines with modest T follicular helper cell responses detectable after Vi-TT only. The Vi-specific IgG and IgM B cell response was considerably greater in magnitude in Vi-TT recipients. Intriguingly, a significant increase in a subset of IgA+ plasma cells expressing mucosal migratory markers α4β7 and CCR10 was observed in both vaccine groups, suggesting a gut-tropic, mucosal response is induced by Vi-vaccination. The total plasma cell response was significantly associated with protection against typhoid fever in Vi-TT vaccinees but not Vi-PS. IgA+ plasma cells were not significantly associated with protection for either vaccine, although a trend is seen for Vi-PS. Conversely, the IgA- fraction of the plasma cell response was only associated with protection in Vi-TT. In summary, these data indicate that a phenotypically heterogeneous response including both gut-homing and systemic antibody secreting cells may be critical for protection induced by Vi-TT vaccination.
Copyright © 2020 Cross, Verheul, Leipold, Obermoser, Jin, Jones, Starr, Mohorianu, Blohmke, Maecker, Napolitani, Hill and Pollard.

Entities:  

Keywords:  CyTOF; ELISpot assay; Salmonella Typhi; Vi-conjugate vaccine; mass cytometry; typhoid fever

Year:  2020        PMID: 33424833      PMCID: PMC7793947          DOI: 10.3389/fimmu.2020.574057

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  53 in total

Review 1.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

2.  Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum.

Authors:  T Nieminen; J Eskola; H Käyhty
Journal:  Vaccine       Date:  1998-04       Impact factor: 3.641

3.  Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2).

Authors:  W Wang; H Soto; E R Oldham; M E Buchanan; B Homey; D Catron; N Jenkins; N G Copeland; D J Gilbert; N Nguyen; J Abrams; D Kershenovich; K Smith; T McClanahan; A P Vicari; A Zlotnik
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

4.  Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens.

Authors:  N Decroix; H Hocini; C P Quan; B Bellon; M D Kazatchkine; J P Bouvet
Journal:  Scand J Immunol       Date:  2001-04       Impact factor: 3.487

5.  Blood-borne human plasma cells in steady state are derived from mucosal immune responses.

Authors:  Henrik E Mei; Taketoshi Yoshida; Wondossen Sime; Falk Hiepe; Kathi Thiele; Rudolf A Manz; Andreas Radbruch; Thomas Dörner
Journal:  Blood       Date:  2008-11-05       Impact factor: 22.113

6.  Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells.

Authors:  Jaime A Tobar; Pablo A González; Alexis M Kalergis
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

Review 7.  Role of beta7 integrins in intestinal lymphocyte homing and retention.

Authors:  G Gorfu; J Rivera-Nieves; K Ley
Journal:  Curr Mol Med       Date:  2009-09       Impact factor: 2.222

8.  Fundamentals of vaccine immunology.

Authors:  Angela S Clem
Journal:  J Glob Infect Dis       Date:  2011-01

9.  Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection.

Authors:  Laila N Abudulai; Sonia Fernandez; Karli Corscadden; Sally A Burrows; Michael Hunter; M Christian Tjiam; Lea-Ann S Kirkham; Jeffrey J Post; Martyn A French
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

10.  Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.

Authors:  Anu Kantele; Sari H Pakkanen; Riitta Karttunen; Jussi M Kantele
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more
  3 in total

1.  Scalable production and immunogenicity of a cholera conjugate vaccine.

Authors:  Suhi Jeon; Meagan Kelly; Jeesun Yun; Byungman Lee; Minchul Park; Yoonhee Whang; Chankyu Lee; Yuan-Di Halvorsen; Smriti Verma; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Daniel T Leung; Taufiqur R Bhuiyan; Firdausi Qadri; Mohammad Kamruzzaman; Somyoung Cho; Willie F Vann; Peng Xu; Pavol Kováč; Ravi Ganapathy; Julia Lynch; Edward T Ryan
Journal:  Vaccine       Date:  2021-10-27       Impact factor: 3.641

Review 2.  Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies.

Authors:  Marcelo B Sztein; Jayaum S Booth
Journal:  Front Microbiol       Date:  2022-09-20       Impact factor: 6.064

3.  The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications.

Authors:  Yanis Feraoun; Jean-Louis Palgen; Candie Joly; Nicolas Tchitchek; Ernesto Marcos-Lopez; Nathalie Dereuddre-Bosquet; Anne-Sophie Gallouet; Vanessa Contreras; Yves Lévy; Frédéric Martinon; Roger Le Grand; Anne-Sophie Beignon
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.